- Half Year 2023 Mithra Pharmaceuticals SA Earnings Call TranscriptSep 26, 2023€1.77 (-15.00%)Earnings
- Q4 2022 Mithra Pharmaceuticals SA Earnings Call TranscriptMar 07, 2023€3.09 (+13.39%)Earnings
- Mithra Pharmaceuticals SA and Richter Gedeon Vegyeszeti Gyar Nyrt to Discuss Partnership for the Commercialisation of Donesta Presentation TranscriptDec 20, 2022
- Q2 2022 Mithra Pharmaceuticals SA Earnings Call TranscriptSep 23, 2022€6.6 (+2.96%)Earnings
- Full Year 2021 Mithra Pharmaceuticals SA Earnings Call TranscriptMar 08, 2022€13.7 (-12.85%)Earnings
- Mithra Pharmaceuticals SA to Discuss Donesta Top-Line Results Call TranscriptJan 14, 2022
- Half Year 2021 Mithra Pharmaceuticals SA Earnings Call TranscriptSep 24, 2021€17.8 (-3.78%)Earnings
- Full Year 2020 Mithra Pharmaceuticals SA Earnings Call TranscriptMar 09, 2021€23.4 (+9.35%)Earnings
- Half Year 2020 Mithra Pharmaceuticals SA Earnings Call TranscriptSep 24, 2020€16.86 (-1.29%)Earnings
- Mithra Pharmaceuticals SA at Jefferies Healthcare Conference (Virtual) TranscriptJun 03, 2020
Mithra Pharmaceuticals SA to Discuss Donesta Top-Line Results Call Transcript
Hello, and welcome to the Donesta top line efficacy results Phase III. My name is Courtney, and I'll be your coordinator for today's event. Please note that this call is being recorded.
(Operator Instructions)
And I will now hand you over to your host, Benoit Mathieu, Group Investor Relations Manager, to begin today's conference. Thank you.
Good morning, ladies and gentlemen. Welcome to all of you. And as you have seen in our press release this morning, we have decided to organize this webcast in order to present in more details to Donesta top line efficacy results. My name is Benoit Mathieu, Investor Relations Officer, and I'm joining the room by our CEO, Leon Van Rompay; Graham Dixon, our Chief Scientific Officer; and Jean-Michel Foidart, our Chief Business Officer.
This webcast is recorded and will be accessible later today on Mithra's website. I would like to remind you that this webcast is covered by the disclaimer on Slide 2 of this presentation. The format of today
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)